Abstract: A method is described for operating a fuel injection system, in particular of an internal combustion engine, in which fuel under pressure is made available in a pressure reservoir and a fuel pressure prevailing in the pressure reservoir is ascertainable with the aid of a pressure sensor. Fuel is removed from the pressure reservoir over a predefinable pressure reduction time period, measured pressure values are ascertained (determined) with the aid of the pressure sensor at least two different points in time during the pressure reduction period, and an actual fuel pressure at the beginning of the pressure reduction period is inferred from the measured pressure values ascertained (determined) during the pressure reduction period.

Abstract: The present invention relates to new trimethoxyphenyl inhibitors of tyrosine kinase, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: A method and a device for controlling a fuel metering system are described. The fuel metering system includes at least one injector for injecting fuel into an internal combustion engine. An electric current value is applied to the at least one injector, and a rail pressure value is determined based on the electric current value.

Abstract: A method for ascertaining an error in a fuel metering unit of an injection system for an internal combustion engine, wherein the gradients of a first signal representing a physical variable and of a second signal representing a physical variable are determined, and at a predefined magnitude and/or direction of the two gradients an error is recognized.

Abstract: A method for determining a fuel mass of a single injection that has been injected into at least one combustion chamber of a combustion engine with at least one injection under high pressure. The method includes determining a correction variable for the single injection with the aid of a comparison of a measure for the actual amount of the injected fuel of at least one test injection, which takes place due to a measure for a default nominal amount of a desired single injection, and a measure for the nominal amount of the test injection. The method additionally includes executing a plurality of timely directly successive test injections.

Abstract: A method for operating a fuel-injection system, in particular of an internal combustion engine, in which fuel stored inside a pressure reservoir is injected by at least one fuel injector. At least one performance quantity of the fuel injector that is a function of the fuel pressure prevailing inside the pressure reservoir is evaluated in order to infer the fuel pressure.

Abstract: Compounds are disclosed having the general formula R1—X—R2, wherein R1 and R2 are biologically active groups, at least one of which is polypeptidic. X is a non-peptidic polymeric group. R1 and R2 may be the same or different. Preferred R1 and R2 groups are interleukin-1 receptor antagonist, 30 kDa TNF inhibitor, interleukin-2 receptors and CR1 and muteins thereof. Also included are site selectively modified interleukin-1 receptor antagonist and 30 kDa TNF inhibitor.

Abstract: Interleukin-1 inhibitors are provided. Compositions comprising an interleukin-1 inhibitor are provided. Methods of treating a patient comprising administering an interleukin-1 inhibitor are provided.

Abstract: This is a method for treating ophthalmic disorders associated with an excess of IGF-I or IGF-II. The method comprises administering individuals with an IGF excess insulin-like growth factor binding protein (IGFBP). The preferred form is IGFBP-3.

Abstract: The invention provides new methods for the treatment of diabetes mellitus, including type I, type II, and insulin resistant diabetes (both type I and type II). The methods of the invention employ administration of rhIGF-I/IGFBP-3 complex to a subject suffering from the symptoms of diabetes mellitus. Administration of rhIGF-I/IGFBP-3 to a subject suffering from the symptoms of diabetes mellitus results in amelioration or stabilization of the symptoms of diabetes.

Abstract: The present invention involves a method for providing high dose IGF-I therapy by administering a complex of IGF-I and IGFBP-3. The IGF-I/IGFBP-3 complex may be given at unexpectedly high doses without inducing IGF-I-related side effects.

Abstract: The present invention provides a novel method for refolding insulin-like growth factor I (IGF-I) and insulin-like growth factor binding protein 3(IGFBP-3). The method involves mixing of IGF-I and IGFBP-3 together in a cofolding reaction. The inventive cofolding method results in substantially higher yields of correctly folded protein for both molecules and alters the kinetics of refolding. The method includes the production of correctly folded IGF-I, IGFBP-3, and/or IGF-I/IGFBP-3 complex.

Abstract: This is a method for treating catabolic conditions in individuals by administering a composition containing a complex of insulin-like growth factor (IGF) and insulin-like growth factor binding protein-3 (IGFBP-3).

Abstract: This is a method for enhancing systemic tissue repair in patients with burns, trauma and peptic ulcers, as well as patients about to undergo, is undergoing or just having undergone surgery. The method comprises systemically administering to such individuals a therapeutic composition comprising IGF and IGFBP. The preferred form is IGF-I/IGFBP-3.

Abstract: High molecular weight forms of therapeutic proteins are disclosed which are single-polypeptide-chain proteins that contain the same or similar therapeutic activity as the therapeutic protein. In particular, high molecular weight forms of the human bFGF angiogenic factor are disclosed which are single-polypeptide-chain proteins having at least one active site possessing an activity selected from the group consisting of mitogenic activity, chemotactic activity, angiogenic activity, neurotrophic activity, the ability to stimulate protease synthesis and combinations thereof. The high molecular weight angiogenic factors exhibit substantial homology to and are immunologically equivalent to the native high molecular weight forms isolatable from human hepatoma cells. The high molecular weight angiogenic factors are produced by DNA translation initiating at non-ATG codons and incorporate additional polypeptide sequences N-terminal to the human bFGF factor.

Abstract: High molecular weight forms of therapeutic proteins are disclosed which are single-polypeptide-chain proteins that contain the same or similar therapeutic activity as the therapeutic protein. In particular, high molecular weight forms of the human bFGF angiogenic factor are disclosed which are single-polypeptide-chain proteins having at least one active site possessing an activity selected from the group consisting of mitogenic activity, chemotactic activity, angiogenic activity, neurotrophic, activity, the ability to stimulate protease synthesis and combinations thereof. The high molecular weight angiogenic factors exhibit substantial homology to and are immunologically equivalent to the native high molecular weight forms isolatable from human hepatoma cells. The high molecular weight angiogenic factors are produced by DNA translation initiating at non-ATG codons and incorporate additional polypeptide sequences N-terminal to the human bFGF factor.

Abstract: The invention relates to readily dispersible pigment formulations which are stable to flocculation and are used for pigmenting naturally occurring and synthetic materials, preferably paints and printing inks, plastics and lacquers, in particular stoving lacquers. The pigment formulations contain compounds of the general formula (I) ##STR1## in which Q.sup.1, Q.sup.2 and Q.sup.3 each denote --X--A, --OR.sup.1, --SR.sup.1, halogen, --NR.sup.2 R.sup.3 or a radical Q which is built up from up to 15 trivalent groups (Ia) such that in each case one group (Ia) is bonded via W to a free valency of the next group (Ia) or to the triazine ring of (I) and the other free valencies are bonded to --X--A, --O--R.sup.1, halogen or --NR.sup.2 R.sup.3, at least one radical --X--A being present in (I), and A stands for an aromatic system with 2 to 6 rings and at least 9 ring atoms, or stands for a group of 2 to 3 aromatic ring systems, bonded via O, S, CO, SO, SO.sub.2 or C.sub.1 -C.sub.

Abstract: Addition compounds which are suitable as dispersants for solids in organic media are obtained from polyepoxides based on novolaks having 3 to 11 nuclei and a mixture of aliphatic, aromatic and/or heterocyclic amines.

Abstract: An isolated DNA sequence encoding an angiogenic factor protein consisting of a single-polypeptide-chain protein having at least one active site possessing mitotic and chemotactic activity and the ability to stimulate protease synthesis, wherein said protein consists of the amino acid sequence: ##STR1## In a preferred embodiment, the DNA sequence encodes basic fibroblast growth factor (bFGF).

Abstract: An angiogenic factor is disclosed which is a purified, single-polypeptide-chain protein having at least one active site possessing an activity selected from the group consisting of mitogenic activity, chemotactic activity, the ability to stimulate protease synthesis and combinations thereof. This angiogenic factor exhibits substantial homology to and is immunologically equivalent to the native angiogenic factor isolatable from human placental tissues. The amino acid sequence of this angiogenic factor is also disclosed. In addition, a method for isolation of the purified angiogenic factor from human placental tissues is set forth. Pharmaceutical preparations incorporating this angiogenic factor are described.